• Publications
  • Influence
Strategies for discovering novel cancer biomarkers through utilization of emerging technologies
The introduction of technologies such as mass spectrometry and protein and DNA arrays, combined with our understanding of the human genome, has enabled simultaneous examination of thousands ofExpand
  • 522
  • 14
Proteomics Analysis of Conditioned Media from Three Breast Cancer Cell Lines
A “bottom-up” proteomics approach and a two-dimensional (strong cation exchange followed by reversed-phase) LC-MS/MS strategy on a linear ion trap (LTQ) were utilized to identify and compareExpand
  • 191
  • 8
  • PDF
Identification of Five Candidate Lung Cancer Biomarkers by Proteomics Analysis of Conditioned Media of Four Lung Cancer Cell Lines*
Detection of lung cancer at an early stage is necessary for successful therapy and improved survival rates. We performed a bottom-up proteomics analysis using a two-dimensional LC-MS/MS strategy onExpand
  • 135
  • 8
  • PDF
Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer
Despite widespread interest, few serum biomarkers have been introduced to the clinic over the past 20 years. Each approach to ovarian cancer biomarker discovery has its own advantages andExpand
  • 125
  • 7
  • PDF
Nipple aspirate fluid proteome of healthy females and patients with breast cancer.
BACKGROUND The ductal/alveolar system of the female breast constantly secretes and reabsorbs fluid in nonpregnant/nonlactating women. This fluid, referred to as nipple aspirate fluid (NAF), can beExpand
  • 34
  • 6
  • PDF
"Product ion monitoring" assay for prostate-specific antigen in serum using a linear ion-trap.
While numerous strategies exist for biomarker discovery, the bottleneck to product development and routine use at the clinic is in the verification phase of candidate biomarkers. The aim of thisExpand
  • 76
  • 3
Mining the Ovarian Cancer Ascites Proteome for Potential Ovarian Cancer Biomarkers*S
Current ovarian cancer biomarkers are inadequate because of their relatively low diagnostic sensitivity and specificity. There is a need to discover and validate novel ovarian cancer biomarkers thatExpand
  • 92
  • 3
  • PDF
Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.
OBJECTIVES Ovarian cancer is the most lethal gynecological malignancy in North America. Although survival rates are high when the disease is diagnosed at an early stage, this decreases exponentiallyExpand
  • 35
  • 3
Quantitative mass spectrometry-based assay development and validation: from small molecules to proteins.
Mass spectrometry (MS) has emerged as a powerful analytical tool for the identification, characterization and quantification of various biomolecules (small molecules, drug metabolites and proteins)Expand
  • 21
  • 3
Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum.
OBJECTIVES The aim of this study was to develop high-throughput, quantitative and highly selective mass spectrometric, targeted immunoassays for clinically important proteins in human plasma orExpand
  • 89
  • 2